![Attralus Receives FDA and EMA Orphan Designation for AT-01 (Iodine (I-124) Evuzamitide), an Investigational Diagnostic for the Management of AL and ATTR Amyloidosis](https://attralus.com/wp-content/uploads/2022/12/AT-01-FDA-EMA-ODD-Press-Release-1080x675.png)
![Attralus Receives FDA and EMA Orphan Designation for AT-01 (Iodine (I-124) Evuzamitide), an Investigational Diagnostic for the Management of AL and ATTR Amyloidosis](https://attralus.com/wp-content/uploads/2022/12/AT-01-FDA-EMA-ODD-Press-Release-1080x675.png)
Recent Posts
- Attralus Presents New Data on Its Pan-Amyloid Therapeutic and Diagnostic Candidates at the XIX International Symposium on Amyloidosis (ISA)
- Clinical Trial Design of AT-02 Phase 2 Open-Label Extension Study in Systemic Amyloidosis
- Relationship Between Myocardial 124I-evuzamitide Uptake and Extracellular Volume Fraction: A Cardiac PET/MRI Study
- Preliminary Evaluation of 99mTc-Labeled Peptide p5+14 (AT-05) for the Detection of Cardiopulmonary Amyloidosis Using SPECT/CT and Planar Gamma Scintigraphic Imaging
- Temporal Changes in Cardiac Amyloid Burden Assessed Using 124I-Evuzamitide PET/CT
Recent Comments
No comments to show.